NYSE:NUVB Nuvation Bio (NUVB) Stock Price, News & Analysis $1.96 +0.17 (+9.22%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$1.98 +0.02 (+1.02%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nuvation Bio Stock (NYSE:NUVB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nuvation Bio alerts:Sign Up Key Stats Today's Range$1.84▼$2.0150-Day Range$1.73▼$2.5352-Week Range$1.54▼$3.97Volume12.71 million shsAverage Volume2.78 million shsMarket Capitalization$665.21 millionP/E RatioN/ADividend YieldN/APrice Target$7.17Consensus RatingBuy Company OverviewNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Read More… Nuvation Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreNUVB MarketRank™: Nuvation Bio scored higher than 69% of companies evaluated by MarketBeat, and ranked 907th out of 2,787 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingNuvation Bio has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuvation Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nuvation Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nuvation Bio are expected to decrease in the coming year, from ($0.36) to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvation Bio is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvation Bio is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvation Bio has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nuvation Bio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.67% of the float of Nuvation Bio has been sold short.Short Interest Ratio / Days to CoverNuvation Bio has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvation Bio has recently increased by 11.90%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvation Bio does not currently pay a dividend.Dividend GrowthNuvation Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.67% of the float of Nuvation Bio has been sold short.Short Interest Ratio / Days to CoverNuvation Bio has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvation Bio has recently increased by 11.90%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment0.31 News SentimentNuvation Bio has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Nuvation Bio this week, compared to 4 articles on an average week.Search Interest18 people have searched for NUVB on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat Follows7 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Nuvation Bio insiders have bought 1,536.00% more of their company's stock than they have sold. Specifically, they have bought $818,000.00 in company stock and sold $50,000.00 in company stock.Percentage Held by Insiders29.93% of the stock of Nuvation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvation Bio's insider trading history. Receive NUVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address NUVB Stock News HeadlinesNuvation Bio jumps after insiders purchase shares worth over $1.1MJune 20 at 12:53 PM | msn.comFounder of Nuvation Bio David Hung Buys More StockJune 20 at 7:53 AM | finance.yahoo.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.June 21, 2025 | Porter & Company (Ad)Nuvation Bio (NYSE:NUVB) Raised to Moderate Buy at Royal Bank Of CanadaJune 19 at 1:57 AM | americanbankingnews.comNuvation Bio price target lowered to $6 from $10 at RBC CapitalJune 18 at 8:34 PM | investing.comNuvation Bio: A Justified Fall Based On Post-Marketing RequirementsJune 18 at 3:48 PM | seekingalpha.comNuvation Bio Inc. (NYSE:NUVB) Given Average Recommendation of "Buy" by AnalystsJune 17, 2025 | americanbankingnews.comOnco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.June 16, 2025 | globenewswire.comSee More Headlines NUVB Stock Analysis - Frequently Asked Questions How have NUVB shares performed this year? Nuvation Bio's stock was trading at $2.66 on January 1st, 2025. Since then, NUVB stock has decreased by 26.5% and is now trading at $1.9550. View the best growth stocks for 2025 here. How were Nuvation Bio's earnings last quarter? Nuvation Bio Inc. (NYSE:NUVB) announced its earnings results on Wednesday, May, 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.16). The business had revenue of $3.08 million for the quarter, compared to analysts' expectations of $0.42 million. Nuvation Bio had a negative net margin of 5,534.21% and a negative trailing twelve-month return on equity of 44.14%. Read the conference call transcript. Who are Nuvation Bio's major shareholders? Nuvation Bio's top institutional shareholders include Vanguard Group Inc. (4.55%), MPM Bioimpact LLC (1.37%), Millennium Management LLC (1.11%) and Charles Schwab Investment Management Inc. (0.56%). Insiders that own company stock include David Hung, Oleg Nodelman, Xiangmin Cui, Kim D Blickenstaff, Robert Mashal and Dongfang Liu. View institutional ownership trends. How do I buy shares of Nuvation Bio? Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuvation Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvation Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/07/2025Today6/20/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSE:NUVB CIK1811063 Webwww.nuvationbio.com Phone332-208-6102FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$7.17 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+266.6%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$567.94 million Net Margins-5,534.21% Pretax Margin-5,534.21% Return on Equity-44.14% Return on Assets-32.97% Debt Debt-to-Equity RatioN/A Current Ratio9.01 Quick Ratio9.01 Sales & Book Value Annual Sales$7.87 million Price / Sales84.52 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book1.43Miscellaneous Outstanding Shares340,260,000Free Float238,422,000Market Cap$665.21 million OptionableOptionable Beta1.37 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NYSE:NUVB) was last updated on 6/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.